Tactile Systems Technology, Inc. Overview
Pro stress-test →Tactile Systems Technology develops and commercializes medical devices that treat chronic lymphedema and airway clearance conditions, focusing on home-based, clinically validated therapies. In 2025, the company achieved 12% revenue growth to $329.5 million, establishing itself as a leader in underserved chronic disease management with strong clinical backing.
Strategic Profile
Pro stress-test →The company offers multiple proprietary devices including Flexitouch Plus for lymphedema treatment, Entre Plus System for compression therapy, Nimbl for upper extremity treatment, and AffloVest for airway clearance. Recently, Tactile acquired LymphaTech Inc. in February 2026 for $6.8 million upfront, adding a 3D measurement platform designed specifically for lymphedema management, strengthening its market position through strategic portfolio expansion.
Competitive Landscape
Pro stress-test →Tactile Medical develops at-home therapies for chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. The company operates in a specialized medical device space with limited direct competitors focused specifically on home-based compression and airway clearance therapy. Key competitive positioning relies on brand strength (Flexitouch Plus), clinical evidence, reimbursement relationships, and increasingly, digital health integration through recent acquisitions.
Industry Context
Tactile Systems Technology, Inc. operates in Medical Devices - Therapeutic Compression & Airway Clearance.
Key facts
Founded: 1995 · Headquarters: Minneapolis, US · Employees: 1,037 · Revenue: $329.5M · Market cap: $680M